Carwin Associat Patent-Cliff Exposure & CMS Drug Spending Portfolio
Carwin Associat (US): 5 reconciled FDA prescription therapies, $30.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $30.1M |
| 2024 Medicare Part D Spend | $17.5M |
| 2024 Medicaid Spend | $12.6M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |